AstraZeneca PLC AZN shares dropped 1.66% to £115.84 Monday, on what proved to be an all-around great trading session for the ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...

J.P. Morgan analyst James Gordon has maintained their bullish stance on AZN stock, giving a Buy rating on September 20. James Gordon has given his Buy rating due to a combination of factors ...

All participants had undergone prior rounds of endocrine-based therapy and at least one systemic treatment. Despite falling ...